The accumulation of extracellular amyloid beta (Abeta42) both in brain and in cerebral vessels characterizes Alzheimer's disease (AD) pathogenesis. Recently, the possibility to functionalize nanoparticles (NPs) surface with Abeta42 binding molecules, making them suitable tools for reducing Abeta42 burden has been shown effective in models of AD. Aim of this work consisted in proving that NPs might be effective in sequestering Abeta42 in biological fluids, such as CSF and plasma. This demonstration is extremely important considering that these Abeta42 pools are in continuum with the brain parenchyma with drainage of Abeta from interstitial brain tissue to blood vessel and plasma. In this work, liposomes (LIP) were functionalized as previously shown in order to promote high-affinity Abeta binding, i.e., either with, phosphatidic acid (PA), or a modified Apolipoprotein E-derived peptide (mApo), or with a curcumin derivative (TREG); Abeta42 levels were determined by ELISA in CSF and plasma samples. mApo-PA-LIP (25 and 250 μM) mildly albeit significantly sequestered Abeta42 proteins in CSF samples obtained from healthy subjects (p < 0.01). Analogously a significant binding (∼20%) of Abeta42 (p < 0.001) was demonstrated following exposure to all functionalized liposomes in plasma samples obtained from selected AD or Down's syndrome patients expressing high levels of Abeta42. The same results were obtained by quantifying Abeta42 content after removal of liposome-bound Abeta by using gel filtration chromatography or ultracentrifugation on a discontinuous sucrose density gradient. In conclusion, we demonstrate that functionalized liposomes significantly sequester Abeta42 in human biological fluids. These data may be critical for future in vivo administration tests using NPs for promoting sink effect.

Conti, E., Gregori, M., Radice, I., DA RE, F., Grana, D., Re, F., et al. (2017). Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease. NEUROCHEMISTRY INTERNATIONAL, 108, 60-65 [10.1016/j.neuint.2017.02.012].

Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease

CONTI, ELISA
;
GREGORI, MARIA;DA RE, FULVIO;GRANA, DENISE;RE, FRANCESCA;MASSERINI, MASSIMO ERNESTO;FERRARESE, CARLO;ZOIA, CHIARA PAOLA;TREMOLIZZO, LUCIO
2017

Abstract

The accumulation of extracellular amyloid beta (Abeta42) both in brain and in cerebral vessels characterizes Alzheimer's disease (AD) pathogenesis. Recently, the possibility to functionalize nanoparticles (NPs) surface with Abeta42 binding molecules, making them suitable tools for reducing Abeta42 burden has been shown effective in models of AD. Aim of this work consisted in proving that NPs might be effective in sequestering Abeta42 in biological fluids, such as CSF and plasma. This demonstration is extremely important considering that these Abeta42 pools are in continuum with the brain parenchyma with drainage of Abeta from interstitial brain tissue to blood vessel and plasma. In this work, liposomes (LIP) were functionalized as previously shown in order to promote high-affinity Abeta binding, i.e., either with, phosphatidic acid (PA), or a modified Apolipoprotein E-derived peptide (mApo), or with a curcumin derivative (TREG); Abeta42 levels were determined by ELISA in CSF and plasma samples. mApo-PA-LIP (25 and 250 μM) mildly albeit significantly sequestered Abeta42 proteins in CSF samples obtained from healthy subjects (p < 0.01). Analogously a significant binding (∼20%) of Abeta42 (p < 0.001) was demonstrated following exposure to all functionalized liposomes in plasma samples obtained from selected AD or Down's syndrome patients expressing high levels of Abeta42. The same results were obtained by quantifying Abeta42 content after removal of liposome-bound Abeta by using gel filtration chromatography or ultracentrifugation on a discontinuous sucrose density gradient. In conclusion, we demonstrate that functionalized liposomes significantly sequester Abeta42 in human biological fluids. These data may be critical for future in vivo administration tests using NPs for promoting sink effect.
Articolo in rivista - Articolo scientifico
Alzheimer's disease; Beta amyloid; Liposomes; Sink effect
English
23-feb-2017
2017
108
60
65
partially_open
Conti, E., Gregori, M., Radice, I., DA RE, F., Grana, D., Re, F., et al. (2017). Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease. NEUROCHEMISTRY INTERNATIONAL, 108, 60-65 [10.1016/j.neuint.2017.02.012].
File in questo prodotto:
File Dimensione Formato  
Conti-2017-Neurochemistry International-AAM.pdf

accesso aperto

Descrizione: Research Article
Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Licenza: Creative Commons
Dimensione 2.14 MB
Formato Adobe PDF
2.14 MB Adobe PDF Visualizza/Apri
Conti-2017-Neurochemistry International-VoR.pdf

Solo gestori archivio

Descrizione: Research Article
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 598.7 kB
Formato Adobe PDF
598.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/147489
Citazioni
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 23
Social impact